Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Research Article

Free Access

Follow-Up of Mild Cognitive Impairment and Related Disorders over Four Years in Adults in Their Sixties: The PATH Through Life Study

Anstey K.J.a · Cherbuin N.a · Christensen H.a · Burns R.a · Reglade-Meslin C.a · Salim A.a · Kumar R.a · Jorm A.F.b · Sachdev P.c

Author affiliations

aCentre for Mental Health Research, Australian National University, Canberra, A.C.T., bORYGEN Research Centre, University of Melbourne, Melbourne, Vic., and cSchool of Psychiatry, University of New South Wales and Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, N.S.W., Australia

Corresponding Author

Kaarin J. Anstey, PhD

Centre for Mental Health Research, Australian National University

Building 63, Eggleston Road

Canberra, ACT 0200 (Australia)

Tel. +61 2 6125 8410, Fax +61 2 6125 0733, E-Mail kaarin.anstey@anu.edu.au

Related Articles for ""

Dement Geriatr Cogn Disord 2008;26:226–233

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Abstract

Aims: The study aimed to estimate incidence rates of mild cognitive impairment and related disorders, and conversion to dementia. Methods: The data are drawn from the PATH Through Life Study. Baseline assessment in 2001–2002 included 2,551 participants 60–64 years old with 2,222 participating in a 4-year follow-up. Those screened positive with a cognitive assessment received clinical assessment for diagnoses of mild cognitive disorders (MCD) or dementia using established clinical criteria. Prevalence and incidence rates for the cohort were estimated with predictive regression models. Results: Annual incidence of dementia was 0.25%. Prevalence of mild cognitive impairment was 4.2%, age-associated memory impairment was 2.4%, age-associated cognitive decline was 7.6%, mild neurocognitive disorders occurred in 12.9% and other cognitive disorders in 7.3%. Prevalence of any diagnosis of any MCD (Any-MCD) was 29.5% and the annual incidence rate for Any-MCD was 5.7%. Agreement for specific diagnoses between waves 1 and 2 was fair to poor (0–47.0%), but agreement for Any-MCD over 4 years was 89.0%. Conclusion: MCD diagnoses do not predict dementia at a 4-year follow-up in young-old adults. Prevalence rates for MCD vary greatly depending on the criteria and time of assessment.

© 2008 S. Karger AG, Basel


References

  1. Panza F, D’Introno A, Colacicco AM, Capurso C, Parigi AD, Capurso SA, Caselli RJ, Pilotto A, Scafato E, Capurso A, Solfrizzi V: Cognitive frailty: predementia syndrome and vascular risk factors. Neurobiol Aging 2006;27:933–940.
  2. Levey A, Lah J, Goldstein F, Steenland K, Bliwise D: Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer’s disease. Clin Ther 2006;28:991–1001.
  3. Tuokko HA, McDowell I: An overview of mild cognitive impairment; in Tuokko HA, Hultsch DF (eds): Mild Cognitive Impairment: International Perspectives. New York, Taylor & Francis, 2006, pp 3–28.
  4. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.
  5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  6. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
  7. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC: Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Br J Psychiatry 2003;182:449–454.
  8. Kumar R, Dear KB, Christensen H, Ilschner S, Jorm AF, Meslin C, Rosenman SJ, Sachdev PS: Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: the Personality and Total Health through Life 60+ Study. Dement Geriatr Cogn Disord 2005;19:67–74.
  9. Bruscoli M, Lovestone S: Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004;16:129–140.
  10. Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56:37–42.
  11. Artero S, Petersen R, Touchon J, Ritchie K: Revised criteria for mild cognitive impairment: validation within a longitudinal population study. Dement Geriatr Cogn Disord 2006;22:465–470.
  12. Palmer K, Fratiglioni L, Winblad B: What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand Suppl 2003;179:14–20.
  13. Ganguli M: Mild cognitive impairment and the 7 uses of epidemiology. Alzheimer Dis Assoc Disord 2006;20:S52–S57.
  14. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF: Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59:1594–1599.
  15. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC: Mild cognitive impairment: prevalence and predictive validity according to current approaches. Acta Neurol Scand 2003;108:71–81.
  16. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ: Multiple cognitive deficits during the transition to Alzheimer’s disease. J Intern Med 2004;256:195–204.
  17. Kumar R, Parslow RA, Jorm AF, Rosenman SJ, Maller J, Meslin C, Anstey KJ, Christensen H, Sachdev PS: Clinical and neuroimaging correlates of mild cognitive impairment in a middle-aged community sample: the personality and total health through life 60+ study. Dement Geriatr Cogn Disord 2006;21:44–50.
  18. Zanetti M, Ballabio C, Abbate C, Cutaia C, Vergani C, Bergamaschini L: Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: a 3-year follow-up study. J Am Geriatr Soc 2006;54:580–586.
  19. Lopez OL, Becker JT, Jagust WJ, Fitzpatrick A, Carlson MC, DeKosky ST, Breitner J, Lyketsos CG, Jones B, Kawas C, Kuller LH: Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry 2006;77:159–165.
  20. Schonknecht P, Pantel J, Kruse A, Schroder J: Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry 2005;162:2071–2077.
  21. Jorm AF, Windsor TD, Dear KBG, Anstey KJ, Christensen H, Rodgers B: Age group differences in psychological distress: the role of psychosocial risk factors that vary with age. Psychol Med 2005;35:1253–1263.
  22. Jorm AF, Anstey KJ, Christensen H, Rodgers B: Gender differences in cognitive abilities: the mediating role of health state and health habits. Intelligence 2004;32:7–23.
    External Resources
  23. Anstey KJ, Mack HA, Christensen H, Li SC, Reglade-Meslin C, Maller J, Kumar R, Dear K, Easteal S, Sachdev P: Corpus callosum size, reaction time speed and variability in mild cognitive disorders and in a normative sample. Neuropsychologia 2007;45:1911–1920.
  24. Christensen H, Dear KB, Anstey KJ, Parslow RA, Sachdev P, Jorm AF: Within-occasion intraindividual variability and preclinical diagnostic status: is intraindividual variability an indicator of mild cognitive impairment? Neuropsychology 2005;19:309–317.
  25. Folstein MF, Robins LN, Helzer JE: The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
  26. Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test. San Antonio, Psychological Corporation/Harcourt Brace Jovanovich, 1987.
  27. Smith A: Symbol Digit Modalities Test (SDMT) Manual. Los Angeles, Western Psychological Services, 1982.
  28. Tiffin J: Purdue Pegboard. Examiners Manual. Rosemont, London House, 1968.
  29. Anstey KJ, Dear K, Christensen H, Jorm AF: Biomarkers, health, lifestyle and demographic variables as correlates of reaction time performance in early, middle and late adulthood. Q J Exp Psychol 2005;58A:5–21.
  30. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.
  31. Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737–1744.
  32. Reitan RM: Trail making test results for normal and brain-damaged children. Percept Mot Skills 1971;33:575–581.
  33. Lezak MD: Neuropsychological Assessment. Oxford, Oxford University Press, 1995.
  34. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH: Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc 1989;37:725–729.
  35. Mack WJ, Freed DM, Williams BW, Henderson VW: Boston Naming Test: shortened versions for use in Alzheimer’s disease. J Gerontol 1992;47:P154–P158.
  36. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159–1165.
  37. Rey A: Psychological examination of traumatic encephalopathy. Arch Psychol 1941;28:286–340.
  38. Kertesz A: Western Aphasia Battery. San Antonio, Psychological Corporation, 1983.
  39. Jack CR Jr, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397–1403.
  40. Kral VA: Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962;86:257–260.
  41. Crook T, Bahar H, Sudilovsky A: Age-associated memory impairment: diagnostic criteria and treatment strategies. Int J Neurol 1987;21–22:73–82.
  42. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, American Psychiatric Association, 1994.
  43. Fischer P, Jungwirth S, Zehetmayer S, Weissgram S, Hoenigschnabl S, Gelpi E, Krampla W, Tragl KH: Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007;68:288–291.
  44. Maioli F, Coveri M, Pagni P, Chiandetti C, Marchetti C, Ciarrocchi R, Ruggero C, Nativio V, Onesti A, D’Anastasio C, Pedone V: Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. Arch Gerontol Geriatr 2007;44(suppl 1):233–241.
  45. Rossini PM, Del Percio C, Pasqualetti P, Cassetta E, Binetti G, Dal Forno G, Ferreri F, Frisoni G, Chiovenda P, Miniussi C, Parisi L, Tombini M, Vecchio F, Babiloni C: Conversion from mild cognitive impairment to Alzheimer’s disease is predicted by sources and coherence of brain electroencephalography rhythms. Neuroscience 2006;143:793–803.
  46. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ, Willis RJ, Wallace RB: Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008;148:427–434.
  47. Hanninen T, Koivisto K, Reinikainen KJ, Helkala EL, Soininen H, Mykkanen L, Laakso M, Riekkinen PJ: Prevalence of ageing-associated cognitive decline in an elderly population. Age Ageing 1996;25:201–205.
  48. Kumar R, Jorm AF, Parslow RA, Sachdev PS: Depression in mild cognitive impairment in a community sample of individuals 60–64 years old. Int Psychogeriatr 2006;18:471–480.
  49. Anstey KJ, Luszcz MA: Selective non-response to clinical assessment in the longitudinal study of aging: implications for estimating population levels of cognitive function and dementia. Int J Geriatr Psychiatry 2002;17:704–709.
  50. Jones RN, Gallo JJ: Education bias in the mini-mental state examination. Int Psychogeriatr 2001;13:299–310.
  51. Ferrer E, Salthouse TA, Stewart WF, Schwartz BS: Modeling age and retest processes in longitudinal studies of cognitive abilities. Psychol Aging 2004;19:243–259.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Accepted: June 27, 2008
Published online: September 11, 2008
Issue release date: October 2008

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.